Cannabis and Ulcerative Colitis
Cannabis may ease UC symptoms but does not treat underlying inflammation; standard therapy remains essential.
This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.
People with UC use cannabis because it often feels good—less cramping, better appetite, better sleep. That's real and worth acknowledging. But the evidence shows cannabis treats the feeling of UC, not the disease itself. It does not heal the colon or reduce inflammation markers. Worse, it can mask a worsening flare while damage accumulates. Cannabis has a role only as an adjunct to proven therapy, ideally with your gastroenterologist in the loop.
Not Medical Advice
This article is not medical advice. Ulcerative colitis is a serious, sometimes life-threatening disease. Untreated or undertreated UC raises the risk of severe flares, hospitalization, colectomy, and colorectal cancer. Do not stop or reduce prescribed therapy based on anything you read here. Talk to your gastroenterologist before adding cannabis to your regimen, especially if you take immunosuppressants, biologics, or anticoagulants.
Plain-Language Summary
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that causes ulcers in the colon and rectum, leading to bloody diarrhea, urgency, cramping, and fatigue. People with UC frequently use cannabis: survey data suggest approximately 15–20% of inflammatory bowel disease patients are active users [1][2].
The short version of what we know:
- Cannabis (mostly THC-containing products) helps some patients feel better—less pain, better appetite, better sleep, improved quality of life. Weak / limited
- Small randomized trials show improvement in symptom-reporting scores in UC patients. Weak / limited
- The same trials generally do not show improvement in objective markers of inflammation (C-reactive protein, fecal calprotectin) or in how the colon appears on endoscopy. Strong evidence [3][4]
- No cannabis product is approved anywhere as a treatment for UC.
In short: cannabis may treat how UC feels, not what UC is.
What Probably Works (Relatively Speaking)
Nothing about cannabis in UC reaches the 'strong evidence' level. The best-supported uses are symptomatic and modest:
Improving quality of life and general well-being. A randomized, placebo-controlled trial by Irving et al. (2018) of CBD-rich cannabis extract in mild-to-moderate UC found improvement in patient-reported quality of life scores, though it failed its primary remission endpoint and experienced high dropout due to side effects [3]. Weak / limited
Reducing disease-activity symptom scores. Naftali et al. (2021) randomized patients with moderately active Crohn's disease (a related IBD) to oral CBD vs. placebo for 8 weeks. The CBD group showed improvement in clinical activity indices but no significant change in C-reactive protein or fecal calprotectin [4]. Weak / limited Because Crohn's disease shares inflammatory pathways with UC, the signal may apply to UC, but direct UC evidence is limited.
Pain, appetite, sleep, and nausea. These are symptoms cannabis tends to help across many conditions, not specifically in UC [5]. Weak / limited
These are real benefits for people living with a difficult disease, but they represent symptomatic relief downstream of inflammation, not disease modification.
What Might Work—Uncertain or Mixed
Steroid sparing. Surveys and retrospective case series suggest some patients reduce or discontinue corticosteroid use after starting cannabis [2]. No controlled trial has confirmed this, and causation is unclear. Anecdote
Rectal or topical cannabinoids. Preclinical animal models of colitis show benefit from CB1/CB2 receptor agonists and from CBD, including reduced inflammation and tissue damage [6]. Human trial data is essentially absent. Weak / limited
Pure CBD (no THC). The Irving et al. (2018) trial tested CBD-rich extract in UC; it did not meet its primary endpoint, tolerability was poor, and the signal for efficacy was modest [3]. Weak / limited
Endocannabinoid system modulation as a therapeutic principle. The gut expresses CB1, CB2, and related receptors, and endocannabinoid signaling appears altered in IBD tissue [7]. This is a plausible mechanistic basis for benefit, but plausibility alone does not prove clinical utility. Disputed
What Doesn't Work or Lacks Adequate Evidence
Inducing or maintaining objective remission. Across published randomized trials, cannabis has not produced consistent improvement in endoscopic appearance, C-reactive protein, or fecal calprotectin [3][4][8]. Strong evidence for absence of disease-modifying benefit at studied doses.
Replacing mesalamine, immunomodulators, or biologics. No evidence supports substitution, and observational data raise caution: cannabis users with Crohn's disease had higher rates of surgery, possibly because symptom relief delayed escalation of anti-inflammatory therapy [2]. This concern likely applies to UC. Weak / limited
Mucosal healing marketed by CBD-only products. No human trial supports mucosal healing from CBD in UC. No data
Strain selection (indica vs. sativa) for gut inflammation. The indica/sativa classification does not reliably predict cannabinoid chemistry or clinical effect. See Cannabis and Polypharmacy Risks for more on strain-related folklore. No data
What We Don't Know
- Whether higher doses, longer treatment duration, or different cannabinoid ratios (e.g., CBG-rich, THCV-rich formulations) could produce objective improvement. Published trials have been short (8–10 weeks) and small (typically 20–60 patients).
- Whether rectal or topical delivery directly to inflamed mucosa would succeed where oral and inhaled routes have not.
- Whether cannabis meaningfully interacts with biologics (infliximab, vedolizumab, ustekinumab) or immunomodulators. Interaction via CYP3A4 inhibition is plausible but not well characterized in IBD populations.
- Whether long-term cannabis use alters the natural history of UC—flare frequency, hospitalization, colectomy risk, or colorectal cancer development. No long-term controlled data exists.
- The role of the gut microbiome as a mediator or confound. Preclinical signals are interesting; robust human data are absent.
How Cannabis Compares to Standard UC Treatments
Standard UC therapy has decades of high-quality evidence behind it:
5-Aminosalicylates (mesalamine, sulfasalazine). First-line for mild-to-moderate UC. Induce and maintain remission with strong evidence and favorable safety profiles [9].
Corticosteroids. Induce remission during flares; not used for maintenance due to long-term toxicity.
Immunomodulators (azathioprine, 6-mercaptopurine). Maintenance therapy in patients with steroid-dependent disease.
Biologics and small-molecule agents (infliximab, adalimumab, vedolizumab, ustekinumab, tofacitinib, upadacitinib, ozanimod). Induce and maintain remission with mucosal healing demonstrated in large randomized trials [10].
Cannabis. Has no comparable evidence base. At best, it addresses residual symptoms in patients already on appropriate therapy. Standard treatments modify disease; cannabis treats symptoms. They are not interchangeable.
Cannabis may have a legitimate adjunctive role for residual pain, anxiety, insomnia, or poor appetite in patients already optimized on mesalamine, immunomodulators, or biologics—ideally with gastroenterologist oversight.
Risks and Practical Considerations
Symptom masking (the biggest specific risk in IBD). Cannabis blunts pain and urgency, making a smoldering flare feel manageable while colonic inflammation progresses. This can delay recognition of worsening disease and escalation of anti-inflammatory therapy. Monitor objective markers—fecal calprotectin, C-reactive protein, periodic endoscopy—not just subjective symptoms.
Cannabinoid hyperemesis syndrome (CHS). Chronic heavy users can develop cyclic vomiting and abdominal pain that mimics or overlaps with UC symptoms [11]. Strong evidence
Drug interactions. CBD is a meaningful inhibitor of CYP3A4 and CYP2C19 and can raise plasma levels of tacrolimus, warfarin, and other drugs metabolized by these enzymes [12]. This is relevant if you are on calcineurin inhibitors, anticoagulants, or certain immunosuppressants. See Cannabis and Polypharmacy Risks for details.
Psychiatric effects. THC can worsen anxiety; high doses and frequent use are associated with cannabis use disorder and, in vulnerable individuals, psychosis [13]. See Cannabis and Psychosis Risk for a fuller discussion.
Smoking. Inhaling combusted plant material carries respiratory risks; vaporization or oral administration are generally preferred for medical use.
Pregnancy and breastfeeding. Avoid cannabis. Use during pregnancy is associated with adverse perinatal outcomes [14].
Surgery and anesthesia. Disclose cannabis use to your surgical and anesthesia teams. Chronic use affects anesthetic requirements and post-operative pain management.
If You Consider Adding Cannabis
If you and your gastroenterologist decide to explore cannabis as an adjunct for residual symptoms (not as a primary UC treatment), reasonable principles include:
- Start with a low dose and increase gradually.
- Prefer products with known, verified cannabinoid content (THC and CBD concentrations).
- Avoid very high-THC products, which carry greater psychiatric and CHS risk.
- Track both subjective symptoms and objective markers (fecal calprotectin, CRP, endoscopy if indicated).
- Do not reduce or stop proven UC therapy on your own.
- Disclose cannabis use to your entire care team, including any specialists on biologics or anticoagulants.
- If you experience worsening cramping, diarrhea, or rectal bleeding despite cannabis use, escalate assessment immediately rather than increasing cannabis dose.
Sources
- Peer-reviewed Ravikoff Allegretti J, Courtwright A, Lucci M, Korzenik JR, Levine J. Marijuana use patterns among patients with inflammatory bowel disease. Inflammatory Bowel Diseases. 2013;19(13):2809–2814.
- Peer-reviewed Storr M, Devlin S, Kaplan GG, Panaccione R, Andrews CN. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease. Inflammatory Bowel Diseases. 2014;20(3):472–480.
- Peer-reviewed Irving PM, Iqbal T, Nwokolo C, et al. A randomized, double-blind, placebo-controlled, parallel-group, pilot study of cannabidiol-rich botanical extract in the symptomatic treatment of ulcerative colitis. Inflammatory Bowel Diseases. 2018;24(4):714–724.
- Peer-reviewed Naftali T, Bar-Lev Schleider L, Almog S, Meiri D, Konikoff FM. Oral CBD-rich cannabis induces clinical but not endoscopic response in patients with Crohn's disease, a randomised controlled trial. Journal of Crohn's and Colitis. 2021;15(11):1799–1806.
- Government National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press; 2017.
- Peer-reviewed Borrelli F, Aviello G, Romano B, et al. Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. Journal of Molecular Medicine. 2009;87(11):1111–1121.
- Peer-reviewed Di Marzo V, Piscitelli F. The endocannabinoid system and its modulation by phytocannabinoids. Neurotherapeutics. 2015;12(4):692–698.
- Peer-reviewed Kafil TS, Nguyen TM, MacDonald JK, Chande N. Cannabis for the treatment of ulcerative colitis. Cochrane Database of Systematic Reviews. 2018;11:CD012954.
- Peer-reviewed Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. American Journal of Gastroenterology. 2019;114(3):384–413.
- Peer-reviewed Singh S, Murad MH, Fumery M, et al. First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis. Clinical Gastroenterology and Hepatology. 2020;18(10):2179–2191.
- Peer-reviewed Sorensen CJ, DeSanto K, Borgelt L, Phillips KT, Monte AA. Cannabinoid hyperemesis syndrome: diagnosis, pathophysiology, and treatment—a systematic review. Journal of Medical Toxicology. 2017;13(1):71–87.
- Peer-reviewed Brown JD, Winterstein AG. Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. Journal of Clinical Medicine. 2019;8(7):989.
- Peer-reviewed Volkow ND, Baler RD, Compton WM, Weiss SRB. Adverse health effects of marijuana use. New England Journal of Medicine. 2014;370(23):2219–2227.
- Government American College of Obstetricians and Gynecologists. Committee Opinion No. 722: Marijuana Use During Pregnancy and Lactation. Obstetrics & Gynecology. 2017;130:e205–e209.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
- Cannabis and Psychosis Risk — THC raises psychosis risk in a dose-dependent manner, particularly in vulnerable groups.
- Cannabis for IBS-C (Constipation-Predominant Irritable Bowel Syndrome) — Why THC likely worsens IBS-C despite anecdotal use; what the evidence actually shows.
- Cannabis for Jet Lag — No direct evidence; standard treatments are more effective at resetting your circadian clo...
- Cannabis Pharmacokinetics: How Cannabinoids Move Through the Body — What happens to THC and CBD once they enter your body, route by route.
- THC Dose and Anxiety — Low doses may reduce acute anxiety; higher doses increase it. Evidence is limited, risks a...